Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000019617-25-000427
Filing Date
2025-05-02
Accepted
2025-05-02 09:59:54
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 4709
  Complete submission text file 0000019617-25-000427.txt   6688
Mailing Address 383 MADISON AVENUE NEW YORK NY 10017
Business Address 383 MADISON AVENUE NEW YORK NY 10017 2122706000
JPMORGAN CHASE & CO (Filed by) CIK: 0000019617 (see all company filings)

EIN.: 132624428 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G
SIC: 6021 National Commercial Banks
(CF Office: 02 Finance)

Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Subject) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91484 | Film No.: 25905980
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)